Advantages of Extended-Release Metformin in Patients with Type 2 Diabetes Mellitus

References

• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491–497
   PubMed Web of Science ®Google Scholar
• . Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:16
   PubMed Web of Science ®Google Scholar
• . Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11(4): 338–342
   PubMed Web of Science ®Google Scholar
• . Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29(4): 759–764
   PubMed Web of Science ®Google Scholar
• . Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137(1):25–33
   PubMed Web of Science ®Google Scholar
• . Kim YD, Park KG, Lee YS, . Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes. 2008;57(2): 306–314
   Web of Science ®Google Scholar
• . Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005;44(7):721–729
   PubMed Web of Science ®Google Scholar
• . Davidson J, Howlett H. New prolonged-release metformin improves gastrointestinal tolerability. Brit J Diabetes Vasc Dis. 2004;4(4): 273–277
   Google Scholar
• . Glucophage XR [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2009
   Google Scholar
• . Glumetza [package insert]. Menlo Park, CA: Depomed, Inc; 2008
   Google Scholar
• . Fortamet [package insert]. Atlanta, GA: Shionogi Pharma, Inc; 2010
   Google Scholar
• . Kombiglyze XR [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, and Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010
   Google Scholar
• . Actoplus Met [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; March 2009
   Google Scholar
• . Fujioka K, Brazg RL, Raz I, . Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab. 2005;7(1):28–39
   PubMed Web of Science ®Google Scholar
• . Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther. 2003;25(2):515–529
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131): 854–865
   PubMed Web of Science ®Google Scholar
• . Hsieh CH, He CT, Lee CH, Wu LY, Hung YJ. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism. 2007;56(8):1087–1092
   PubMed Web of Science ®Google Scholar
• . Sweeny M, DeFronzo R, Scinta W. Tolerability of metformin gastro-retentive formulation (M-GR) in patients previously intolerant of metformin [ADA abstract 729-P]. Diabetes. 2010;59( suppl 1):A199
   Google Scholar
• . Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20(4):565–572
   PubMed Web of Science ®Google Scholar
• . Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12(3):239–245
   PubMed Web of Science ®Google Scholar
• . Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich). 2008;10(1 suppl 1):20–26
   Google Scholar
• . Penning-van Beest FJ, van der Bij S, Erkens JA, Kessabi S, Groot M, Herings RM. Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment. Curr Med Res Opin. 2008;24(9):2523–2529
   PubMed Web of Science ®Google Scholar
• . Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25(11):2958–2971
   PubMed Web of Science ®Google Scholar
• . Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–3035
   PubMed Web of Science ®Google Scholar
• . Dúsing R. Adverse events, compliance, and changes in therapy. Curr Hyperten Rep. 2001;3(6):488–492
   Google Scholar
• . Feher MD, Al-Mrayat M, Brake J, Leong KS. Tolerability of prolonged-release metformin (Glucophage SR) in individuals intolerant to standard metformin results from four UK centres. Brit J Diabetes Vasc Dis. 2007;7:225–228
   Google Scholar
• . Shaya FT, Du D, Gbarayor CM, Frech-Tamas F, Lau H, Weir MR. Predictors of compliance with antihypertensive therapy in a high-risk Medicaid population. J Natl Med Assoc. 2009;101(1):34–39
   PubMed Web of Science ®Google Scholar
• . Balu S, Simko RJ, Quimbo RM, Cziraky MJ. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin. 2009;25(11):2765–2775
   PubMed Web of Science ®Google Scholar
• . Hess G, Hill J, Lau H, Dastani H, Chaudhari P. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. P T. 2008;33(11):652–666
   Google Scholar
• . van Santen Barends DM, Frijlink HW. Breaking of scored tablets: a review. Eur J Pharm Biopharm. 2002;53(2):139–145
   Google Scholar
• . Rodenhuis N, De Smet PA, Barends DM. The rationale of scored tablets as dosage form. Eur J Pharm Sci. 2004;21(2–3):305–308
   PubMed Web of Science ®Google Scholar